交易 Janux Therapeutics, Inc. - JANX 差價合約

交易條件

• 類型: 差價合約
• 點差: 0.10
• 長倉隔夜倉息調整: -0.02154%
• 短倉隔夜倉息調整: -0.00068%
• 隔夜倉息調整時間: 21:00 (UTC)
• 貨幣: USD
• 最低成交量: 0.1
• 保證金: 50.00%
• 證券交易所: United States of America
• 交易佣金: 0%
• 保證止損溢價: 1%

主要統計數據

• 前收盤價: 13.9
• 開倉: 13.99
• 1 年變化: -55.84%
• 日區間: 13.53 - 13.99

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company''s lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.